Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases

Case Reports in Oncology

Volumn 7, Issue 1, 2014, Pages 97-101

  Callegaro Filho, Donato ^a   Kavanagh, John J ^b   Nick, Alpa M ^c   Ramirez, Pedro T ^c   Schmeler, Kathleen M ^c  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor inhibitor; Erlotinib; Maintenance therapy; Recurrent cervical cancer

Indexed keywords

CISPLATIN; ERLOTINIB; TOPOTECAN;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CHEMORADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE SEVERITY; DISTANT METASTASIS; DRUG TOLERABILITY; FATIGUE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; RADIATION FIELD; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; UTERINE CERVIX CARCINOMA;

EID: 84900496801     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000358916     Document Type: Article

References (13)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69.
2. Hong JH, Tsai CS, Lai CH, et al: Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:249.
3. Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008;34:603-613.
4. Tewari KS, Sill M, Long HJ, et al: Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;31(suppl; abstr 3).
5. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
7. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
8. Pérol M, Chouaid C, Pérol D, et al: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516-3524.
9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
10. Kersemaekers A, Fleuren G, Kenter G, et al: Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res 1999;5:577-586.
11. Sizemore N, Choo C, Eckert R, Rorke E: Transcriptional regulation of the EGF receptor promoter by HPV16 and retinoic acid in human ectocervical epithelial cells. Exp Cell Res 1998;244:349-356.
12. Schilder R, Sill M, Lee Y, Mannel R: A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009;19:929-933.
13. Rodrigues A, Small I, Carmo C, et al: INCA-GYN001: erlotinib added to cisplatin and definitive radiotherapy in untreated patients with locally advanced squamous cell cervical carcinoma-final report of a phase II trial. J Clin Oncol 2011;29:(suppl; abstr 5033).